Do commonly used prostate medications alter prostate MRI and fusion biopsy performance?

• Published in: Clinical nephrology Vol. 97; no. 6; pp. 339 - 345
• Main Authors: Krughoff, Kevin, Buller, Dylan M., Wu, Shuo-Chieh, Rodriguez, Roberto, Kilchevsky, Amichai, Santis, William F., Sverrisson, Einar F., Seigne, John D., Wagner, Joseph R., Dagrosa, Lawrence M.
• Format: Journal Article
• Language: English
• Published: Nubich Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 01.06.2022
• Subjects: Biopsy; Magnetic resonance imaging; Prostate
• ISSN: 0301-0430
• DOI: 10.5414/CN110665

Aims: To determine whether phosphodiesterase inhibitors (PDEi) or α-antagonists (AA) were associated with differences in region of interest (ROI) characteristics or prostate cancer detection on fusion biopsy (FB).Materials and methods: Records from 847 consecutive patients undergoing FB at three separate institutions over a period of 2 years were retrospectively reviewed. Associations between medication use, Prostate Imaging Reporting & Data System (PIRADS) scores, and ROI locations were assessed with ordinal logistic regression. Associations with lesion size and International Society of Urologic Pathology (ISUP) grade group (GG) on biopsy were tested using multivariate regression.Results: Medication use included PDEi in 14.2% and AA in 23.0%. PDEi use was associated with 19.3% smaller lesion diameter (–2.8 mm; CI from –4.8 to –0.7; p < 0.01) and lower PIRADS scores on MRI (OR 0.60; CI 0.40 – 1.00; p = 0.05). AA use was associated with higher PIRADS scores (OR 1.43; CI 0.97 – 2.11; p = 0.06), fewer positive fusion-directed biopsy cores (–28.6%, CI from –57.9 to 0.01%, p = 0.05), and downgrading on final pathology (–19%; CI from –40 to 2%; p = 0.06).Conclusion: For PIRADS scores ≥ 3, PDEi use is associated with smaller ROI and lower PIRADS scores, while AA use is associated with higher PIRADS scores. Neither medication was associated with differences in biopsy GG. Prospective studies are needed to investigate the discordance between multi-parametric magnetic resonance imaging (mpMRI) results and oncologic outcomes associated with PDEi and AA use.